key: cord-0750689-u5inoxg9 authors: Shoraka, Shahrzad; Ferreira, Maria Lucia Brito; Mohebbi, Seyed Reza; Ghaemi, Amir title: SARS-CoV-2 Infection and Guillain-Barré Syndrome: A Review on Potential Pathogenic Mechanisms date: 2021-05-10 journal: Front Immunol DOI: 10.3389/fimmu.2021.674922 sha: 9d07a37f4c9467f8e572126cd65bc7ac39a1d83e doc_id: 750689 cord_uid: u5inoxg9 Since December 2019, the world has been facing an outbreak of a new disease called coronavirus disease 2019 (COVID-19). The COVID-19 pandemic is caused by a novel beta-coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The SARS-CoV-2 infection mainly affects the respiratory system. Recently, there have been some reports of extra-respiratory symptoms such as neurological manifestations in COVID-19. According to the increasing reports of Guillain-Barré syndrome following COVID-19, we mainly focused on SARS-CoV-2 infection and Guillain-Barré syndrome in this review. We tried to explain the possibility of a relationship between SARS-CoV-2 infection and Guillain-Barré syndrome and potential pathogenic mechanisms based on current and past knowledge. Over the past two decades, coronaviruses have caused three epidemic diseases named the severe acute respiratory syndrome (SARS), the Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19) (1). All these three diseases are caused by coronaviruses belonging to the beta genus (2, 3) . Infections caused by these beta-coronaviruses show a variable range of clinical manifestations, from being asymptomatic to severe disease and death (4) . Although pulmonary symptoms are considered the main clinical manifestation, neurological complications associated with these three respiratory coronaviruses have also been reported (2, 5) . In this review, we mainly focused on SARS-CoV-2 infection and Guillain-Barrésyndrome and tried to explain the potential pathogenic mechanisms based on current and past knowledge. The prevalence of neuro-COVID has been reported to vary between studies. Although the prevalence rate of neurological symptoms is estimated to be around 3.5 to 84% among COVID-19 patients, in most cases the SARS-CoV-2 RNA was not detected in the cerebrospinal fluid (CSF) (28, 30, 31) . Among 58 patients with COVID-19 and neurological symptoms, the SARS-CoV-2 RNA was detected in CSF of 2 patients (3.4%). One patient with refractory headache and another with ADEM four days after the onset of COVID-19 symptoms (32) . Also Domingues et al. detected SARS-CoV-2 in CSF using by RT-PCR and confirmed with deep sequenced. There was a 99.74 to 100% similarity between the patient virus to the worldwide sequences (33) . On the other hand, organoids and in vivo studies in human ACE2 transgenic mice have demonstrated that the SARS-CoV-2 could infect neurons and contribute to cell death and neural damage. However, CSF and autopsy findings do not provide consistent support for direct CNS invasion. So SARS-CoV-2 related neurological symptoms may be the consequences of different mechanisms (18, 29, 34) . Given that coronaviruses could lead to short-or long-term neurological disorders, there was a hypothesis that these viruses may have neurovirulence because of the neurotropism and neuroinvasion of human coronaviruses (35) (36) (37) (38) (39) . Since 2000, Arbour et al. found HCoV RNA in brain samples outside blood vessels, and affirmed the consistence of neuroinvasion by these respiratory pathogens in humans but considered the need of further studies to distinguish between opportunistic and disease-associated viral presence (40) . It seems that coronaviruses could be responsible for direct and indirect neurological symptoms and complications with central nervous system (CNS) (including headache, epileptic seizure, impaired consciousness and dizziness) and peripheral nervous system (PNS) manifestations (such as Guillain-Barreś yndrome, anosmia and neuralgia) (41) , divided as parainfectious and post-infectious (5, 8, 23, 34, (42) (43) (44) (45) ) (see Figure 1 ). During the SARS-CoV and MERS-CoV outbreak, some neurological symptoms were among their other extra-pulmonary complications ( Table 1) . At the present SARS-Cov-2 outbreak, there have been increasing reports of clinical neurological disorders such as acute encephalomyelitis, acute flaccid paralysis (AFP), multiple sclerosis (MS), acute demyelinating encephalomyelitis (ADEM), and Guillain-Barrésyndrome (GBS) as possible complications, supporting its neuroinvasion nature (12, 40, (51) (52) (53) . Among them, Guillain-BarréSyndrome is the most frequent. infection (54) . In fact, GBS is symmetrical ascending paralysis, often caused by respiratory or gastrointestinal infections from a virus or bacteria (4). Many bacteria and viruses have been considered as possible trigger of GBS (55, 56) . Before the recent pandemic, few cases of coronavirus associated to GBS were reported, but a systematic review pointed a significant increasing number of patients with GBS after the COVID-19 pandemic, with higher prevalence among older patients (mean age of 60 years) than with younger ones (mean age of 40 years) (57) ( Table 2) . GBS associated to SARS-CoV-2 infection may follow the typical post-infectious pattern, with report indicating that it is also possible in children. GBS has also been reported as part of the "long COVID-19 syndrome" (69, 73) . Nevertheless, there are also reports that GBS is a para-infectious paralysis associated with a viral infection (74) . Almost all reported cases have acute onset within a few days of onset of viral infection (75) (see Figure 2 ). Molecular mimicry between microbial and neural antigens is a major driving force in this disorder. The interaction between microbial agents and the host that dictates the immune response to the unwanted auto reactivity is not well understood yet. On the other hand, most people (>99%) who are exposed to immune stimulus, as a result of GBS-associated infection do not develop unwanted autoimmunity. It seems that genetics and environmental factors affect the susceptibility of individual to this disease (56, 76, 77) . The association of various microorganisms with Guillain-Barrésyndrome has been reported such as Campylobacter jejuni (C. jejuni), Mycoplasma pneumoniae, Haemophilus influenza, Cytomegalovirus (CMV), Epstein-Barr virus (EBV), influenza A, varicella-zoster, hepatitis (A, B and E), Zika and Chikungunya viruses (78) (79) (80) (81) (82) (83) (84) (85) (86) (87) (88) (89) (90) (91) . C. jejuni has been identified as the most common pathogen causing this disorder (91, 92) . In 2001, Yuki showed that the core lipo-oligosaccharides of the Campylobacter jejuni strains associated with GBS have structural similarities to various gangliosides in peripheral nerve membranes, suggesting that molecular mimicry of gangliosides may contribute to GBS (93) . Molecular mimicry of gangliosides in C. jejuni results in the production of anti-ganglioside antibodies that bind to gangliosides in the axonal membrane at the Ranvier node. Activation of complement leads to disruption of voltage-gated sodium channels, disruption of nodal structure, and formation of the membrane attack complex that leads to calcium influx. Eventually, these changes cause axonal damage and attract macrophages, which could then migrate between axon and myelin (80, 94) . Guillain-Barre-associated viral infections show similar mechanisms to bacterial GBS. However, due to the wide range of viral antigens that may be associated with GBS, the pathophysiology, the clinical course, and outcomes may vary (78) . Out of 282 patients with neurological problems, 56 had a COVID-19 positive test. Of these, 23 patients had no symptoms of COVID-19 while 33 had. In both groups, weakness of consciousness was the most common primary neurological symptom FIGURE 1 | Schematic classification of neurological complications associated with coronavirus infections. Coronaviruses could directly or indirectly affect the CNS and/or PNS and lead to post-or para-infectious neurological complications. The concept appears to be generalizable to SARS-CoV-2 as well. Studies have described the role of GM2 anti-glycoside antibodies in the pathogenesis of CMV-related GBS. The findings of these studies showed that anti-GM2 IgM antibodies are induced in acute cytomegalovirus infection through molecular mimicry between GM2 and the antigens induced by CMV infection (77, 93, 95, 96) . For hepatitis A, B, C, or E, a definite homogeneous epitope with components of the peripheral nerve has not yet been described. However, in 2009, Loly et al. reported the presence of anti-ganglioside GM2 antibodies in hepatitis E virus-related GBS. They have declare a possible molecular mimicry of gangliosides (97) . Over the past decades, studies have demonstrated a possible link between the arthropod-borne viruses (arboviruses) including Zika and Chikungunya virus and the development of GBS (98) (99) (100) (101) (102) . Shortly after the outbreak of ZIKV, in 2015, a cluster of cases with GBS was identified in Brazil (103) . Also, a case-control study in France revealed that out of 42 patients diagnosed with Guillain-Barrésyndrome, 41 (98%) had anti-Zika virus IgM or IgG, and all (100%) had neutralizing antibody against the Zika virus (104) . The analysis of case series from seven countries showed that the changes in the reported incidence of Zika virus disease during 2015 and early 2016 were closely related to the change in the incidence of Guillain-Barrésyndrome (105) . In the case of GBS associated with the Zika virus, several antiganglioside antibodies also are indicated and may play a role in the mechanism of molecular mimicry (104, 106, 107) . In addition, there are other alternative mechanisms described for Zika-related GBS. It could be due to a direct viral neuropathic effect, and cross-reactive antibodies formed during previous infections with a detrimental effect on nerve function. The underlying mechanisms of para-infectious pathogenesis have not yet been identified. It has been suggested that specific Zika virus-peptides may not only cross-react but also induce a cellular immune response via antigen-presenting cell activation of T-lymphocytes (104, 106, 108, 109) . During the recent pandemic, there is also growing evidence that SARS-CoV-2 infection is associated with immune-mediated neurological complications, for example, in the form of GBS (65, 110) . The exact pathogenesis of COVID-19-related neurological damage is still largely unknown. Considering that previous viral outbreaks, molecular mimicry between SARS-CoV-2 and various human organs and tissues have been hypothesized as a potential trigger of multi-organ autoimmunity in COVID-19 (104, (111) (112) (113) (114) . Moreover, failure to detect the SARS-CoV-2 in most of the CSF patient samples supports an immune mechanism rather than direct invasion (18) . In a recent study by Lucchese and Flöel, sequence analysis of the 41 human proteins associated with acute and chronic immune-mediated neuropathies revealed that SARS-CoV-2 contained two immunologically-related hexapeptides (KDKKKK in nucleocapsid and EIPKEE in Orf1ab) with the human heat shock proteins 90 (HSP90B and HSP90B2) and 60 (HSP60), respectively (113) . These authors hypothesized that SARS-CoV-2 infection may trigger an adaptive immune response in which T cell-B cell interactions result in the production specific antibodies similar to ganglioside-peptide sequences or structure, resulting in loss of self-tolerance (113) . The gangliosides located on the membranes of neurons and the Schwann-cells, which form the myelin sheath, act as receptors for antiganglioside antibodies, promoting neutralization of neurons complement inhibitory activity, which turn them into targets for autoimmune-mediated destruction of myelin sheaths or axons (113) . About 50 to 85% of previously reported cases with GBS or its variants have anti-ganglioside antibodies in their serum. However, there are limited data on the presence of antiganglioside antibodies in the patients with COVID-19 related GBS. Studies have not reported increase in the serum titers of anti-ganglioside antibodies in GBS patients with COVID-19. Recently, Dufour et al. reported first case with COVID-19 related GBS with positive GM1 antibody (67, 75) . Therefore, further studies are necessary to confirm the presence of antiganglioside antibodies in COVID-19 related GBS. This molecular mimicry has also been shown in the implication of HSPs in some immune-mediated clinical conditions (115) . A 2015 study by Loshaj-Shala et al. reported a high homology between C. jejuni DnaK and GroEL with the human peripheral nerve HSP70 and HSP60, respectively. These results strongly support the potential role of chaperone molecules in the progression of the autoimmune response related to GBS (92) . Also an etiological relationship between some neurological diseases and autoantibodies against HSP family proteins has sometimes been described (116, 117) . It is noteworthy that autoantibodies targeting different families of HSPs were increased in serum and CSF of patients with GBS compared to healthy controls (118, 119) . In a study, Yonekura et al. demonstrated that IgG and IgM antibody titers against several HSPs (including HSP60) were significantly higher in the CSF of patients with GBS in the acute phase than patients with motor neuron diseases (MND) (120) . The sharing of peptide motifs with immunologic potential between SARS-CoV-2 and HSPs strongly supports immunemediated neuronal damage (121) . The role of neuroinflammation and the effect of cytokine storm caused by SARS-CoV-2 infection on the nervous system have been discussed. In COVID-19 patients, an increase has been observed in cytokines such as interleukin-1b (IL-1b), IL-6, IL-17, TNF-a and interferon-g (IFN-g), along with other chemokines. Because many of the same cytokines have been implicated in the pathogenesis of typical GBS, the cytokine storm in COVID-19 may play a pivotal role in the simultaneous development and progression of GBS (75). Zhang et al. in 2013 reported elevated serum TNF-a levels during acute phase of GBS and it was associated with clinical severity of the disease (122) . CSF levels of IFN-g, IL-4, IL-17, and IL-22 are increased in GBS, and IL-17 and IL-22 levels are associated with disease severity (123) (124) (125) . However, the role of cytokines in COVID-19 related GBS needs further investigation (126, 127) . Here, we describe the possible mechanisms that may be involved in the development of Guillain-Barrésyndrome following the SARS-CoV-2 infection. Further studies are needed to better understand the possible mechanism of this relation. To confirm the exact pathogenic mechanism, identification of T cell responses, or particular antibodies to the target autoantigen; recognition of structural homology between the infectious agent and the target autoantigen and, finally, reproduction of the disease following immunization with the infectious agent in an animal model should be considered (128) . During the recent pandemic, many cases of Guillain-Barreś yndrome have been reported to be associated with COVID-19. In this review article, we have discussed the possibility of a relationship between SARS-CoV-2 infection and Guillain-Barreś yndrome and potential pathogenic mechanisms based on current and past knowledge. It is noteworthy that during the recent pandemic, there have been several case reports of the para-infectious pattern of GBS according to SARS-CoV-2 infection. On the other hand, GBS may be part of the "long COVID-19 syndrome". Therefore, Guillain-Barrésyndrome associated with SARS-CoV-2 in addition to the classic postinfectious profile might follow the pattern of a para-infectious as reported in Guillain-Barrésyndrome associated with the Zika virus. Identifying and linking para-and post-infectious neurological diseases such as GBS to a pandemic is confusing. Besides, accurate and timely diagnosis is critical. Therefore, considering that there may be a link between SARS-CoV-2 infection and GBS is helpful in rapid diagnosis of patients. We have also highlighted that the possible role of indirect immunemediated mechanisms, such as molecular mimicry and neuroinflammation, is more than direct viral invasion in the development of COVID-19 related GBS. Also further molecular studies are needs to investigate the exact mechanism that leads to the GBS following the SARS-CoV-2 infection. In conclusion, although many studies support the link between SARS-CoV-2 infection and GBS, more evidence is needed to confirm their relationship and describe its exact mechanism. Epidemiological evidence associated with the suspected infectious agent and GBS should be considered to approve the association between COVID-19 and GBS. However, based on recent reports, we suggest that all newly diagnosed Guillain-Barrécases should be tested for SARS-CoV-2 infection in the current pandemic, even if they have no respiratory complaints. SRM: article decision, planning, and writing. SHSH: literature search and reviewing and article writing. MLBF: manuscript revision on Neurology. AGH: article reviewing. All authors contributed to the article and approved the submitted version. SARS and MERS: Recent Insights Into Emerging Coronaviruses MERS and COVID-19: Clinical Manifestations and Organ-System Complications: A Mini Review Review of the 2019 Novel Coronavirus (SARS-CoV-2) Based on Current Evidence Neurologic Complications of COVID-19 COVID-19, SARS and MERS: A Neurological Perspective Coronavirus Disease 2019: What We Know Novel Coronavirus (COVID-19) Outbreak: A Review of the Current Literature Potential Neurological Manifestations of COVID-19 An Overview of Their Replication and Pathogenesis Guillain-Barré Syndrome and SARS-CoV-2 SARS-CoV-2: Rapid Classification of Betacoronaviruses and Identification of Traditional Chinese Medicine as Potential Origin of Zoonotic Coronaviruses Molecular Immune Pathogenesis and Diagnosis of COVID-19 Coronavirus Infections-More Than Just the Common Cold Molecular Evolution of Human Coronavirus Genomes Novel Coronavirus: From Discovery to Clinical Diagnostics Coronavirus Disease 2019 (COVID-19) Pandemic Implications in Pediatric and Adult Congenital Heart Disease Chronic Kidney Disease is Associated With Severe Coronavirus Disease 2019 (COVID-19) Infection Liver Injury During Highly Pathogenic Human Coronavirus Infections Effects of COVID-19 on the Nervous System A New Coronavirus Associated With Human Respiratory Disease in China A Pneumonia Outbreak Associated With a New Coronavirus of Probable Bat Origin Neurological Insights of COVID-19 Pandemic Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation Clinical Features of Patients Infected With 2019 Novel Coronavirus in Wuhan The Neuroinvasive Potential of SARS-CoV2 may Play a Role in the Respiratory Failure of COVID-19 Patients Extra-Respiratory Manifestations of COVID-19 Cardiovascular Complications in COVID-19 Renal Involvement and Early Prognosis in Patients With COVID-19 Pneumonia Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal Fluid Infectivity of Human Coronavirus in the Brain Central and Peripheral Nervous System Complications of COVID-19: A Prospective Tertiary Center Cohort With 3-Month Follow-Up Cytokine Release Syndrome-Associated Encephalopathy in Patients With COVID-19 Cerebrospinal Fluid Findings in Neurological Diseases Associated With COVID-19 and Insights Into Mechanisms of Disease Development First Case of SARS-COV-2 Sequencing in Cerebrospinal Fluid of a Patient With Suspected Demyelinating Disease COVID-19 Pandemic: A Neurological Perspective Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System? Neurological Manifestations of COVID-19, SARS and MERS Tracing New Clinical Manifestations in Patients With COVID-19 in Chile and Its Potential Relationship With the SARS-CoV-2 Divergence Neuroinvasive and Neurotropic Human Respiratory Coronaviruses: Potential Neurovirulent Agents in Humans Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System? Neuroinvasion by Human Respiratory Coronaviruses Evidence of Central Nervous System Infection and Neuroinvasive Routes, as Well as Neurological Involvement, in the Lethality of SARS-CoV-2 Infection Neurological Manifestations in COVID-19 Caused by SARS-CoV-2 Potential Neurological Impact of Coronaviruses: Implications for the Novel SARS-CoV-2 Human Coronaviruses: Viral and Cellular Factors Involved in Neuroinvasiveness and Neuropathogenesis COVID-19 and Nervous System: Under Estimated Clinical and Prognostic Aspects Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease A Prospective Clinical Study of Detailed Neurological Manifestations in Patients With COVID-19 Neurologic Manifestations in 1760 COVID-19 Patients Admitted to Papa Giovanni XXIII Hospital Clinical Characteristics of 113 Deceased Patients With Coronavirus Disease 2019: Retrospective Study Neurological Manifestations as Primary Presentation of COVID-19 in Hospitalized Patients Detection of Coronavirus in the Central Nervous System of a Child With Acute Disseminated Encephalomyelitis A Rare Cause of Acute Flaccid Paralysis: Human Coronaviruses Guillain-Barré Syndrome and SARS-CoV-2 Guillain-BarreŚ yndrome With Unilateral Peripheral Facial and Bulbar Palsy in a Child: A Case Report Guillain-BarréSyndrome and Related Diseases After Influenza Virus Infection Very Early Guillain-BarréSyndrome: A Clinical-Electrophysiological and Ultrasonographic Study Guillain-BarréSyndrome: Causes, Immunopathogenic Mechanisms and Treatment Relation Between COVID-19 and Guillain-BarréSyndrome in Adults: A Systematic Review Neurological Complications During Treatment of Middle East Respiratory Syndrome Guillain-BarréSyndrome as a Complication of SARS-CoV-2 Infection COVID-19 may Induce Guillain-BarréSyndrome Guillain Barre Syndrome Associated With COVID-19 Infection: A Case Report Guillain-BarréSyndrome Following COVID-19: New Infection, Old Complication? Guillain-BarréSyndrome Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Detection and Coronavirus Disease 2019 in a Child Guillain-BarréSyndrome Related to COVID-19 Infection Vasoactive Intestinal Peptide in Checkpoint Inhibitor-Induced Pneumonitis Guillain-BarréSyndrome and COVID-19: An Observational Multicentre Study From Two Italian Hotspot Regions Gm1 Ganglioside Antibody Systemic Review and Implication for Vaccine Development Guillain Barre Syndrome Following Delivery in a Pregnant Woman Infected With SARS-Cov-2 Late Onset of Guillain-BarreŚ yndrome Following SARS-CoV-2 Infection: Part of 'Long COVID-19 Syndrome Guillain-BarréSyndrome Associated With SARS-CoV-2 Infection: Causality or Coincidence? Early Guillain-BarréSyndrome in Coronavirus Disease 2019 (COVID-19): A Case Report From an Italian COVID-Hospital Parainfectious Guillain Barre Syndrome in a Patient Diagnosed With COVID-19 Guillain-BarréSyndrome Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Detection and Coronavirus Disease 2019 in a Child Concurrent Guillain-BarréSyndrome, Transverse Myelitis and Encephalitis Post-Zika: A Case Report and Review of the Pathogenic Role of Multiple Arboviral Immunity Guillian BarréSyndrome and COVID-19: Possible Role of the Cytokine Storm Cross-Reactive Antibodies Against GM2 and CMVinfected Fibroblasts in Guillain-Barre Syndrome Guillain-BarréSyndrome, Transverse Myelitis and Infectious Diseases Guillain-BarréSyndrome Following Varicella-Zoster Virus Infection Guillain-BarréSyndrome: A Century of Progress Mild Form of Guillain-BarréSyndrome in a Patient With Primary Epstein-Barr Virus Infection The Spectrum of Antecedent Infections in Guillain-BarréSyndrome A Case of Relapsing Guillain-BarréSyndrome Associated With Exacerbation of Chronic Hepatitis B Virus Hepatitis Acute Hepatitis B Presenting as Guillain-BarréSyndrome A Rare Case of Acute Hepatitis B Virus Infection Causing Guillain-BarréSyndrome Guillain-BarreŚ yndrome: Rare Extra-Intestinal Manifestation of Hepatitis B Guillain-Barre Syndrome Associated With Acute Hepatitis A: A Case Report Guillain-BarréSyndrome and Influenza Virus Infection Primary Cytomegalovirus Infection in Patients With Guillain-BarréSyndrome A Rare Case of Infectious Mononucleosis Complicated by Guillain-Barre Syndrome Guillain-BarréSyndrome: Pathogenesis, Diagnosis, Treatment and Prognosis GBS): New Insights in the Molecular Mimicry Between C. Jejuni and Human Peripheral Nerve (HPN) Proteins Infectious Origins of, and Molecular Mimicry in Guillain-Barréand Fisher Syndromes Anti-GM1 Antibodies Cause Complement-Mediated Disruption of Guillain-Barré Syndrome and SARS-CoV-2 Frontiers in Immunology | www.frontiersin.org Sodium Channel Clusters in Peripheral Motor Nerve Fibers Association of anti-GM2 Antibodies in Guillain-Barre Syndrome With Acute Cytomegalovirus Infection Cytomegalovirus Infections and anti-GM2 Antibodies in Guillain-BarréSyndrome Guillain-BarréSyndrome Following Hepatitis E Guillain-BarréSyndrome and Zika Virus Outbreaks Neurological Disease in Adults With Zika and Chikungunya Virus Infection in Northeast Brazil: A Prospective Observational Study Zika Virus and Guillain-BarréSyndrome: Another Viral Cause to Add to the List Long-Term Outcomes of Guillain-BarréSyndrome Possibly Associated With Zika Virus Infection Risk Factor for Guillain-BarréSyndrome Case Report: Guillain-barréSyndrome After Zika Virus Infection in Brazil Guillain-BarréSyndrome Outbreak Associated With Zika Virus Infection in French Polynesia: A Case-Control Study Zika Virus and the Guillain-BarréSyndrome -Case Series From Seven Countries Anti-Ganglioside Antibodies in Patients With Zika Virus Infection-Associated Guillain-BarreŚyndrome in Brazil Antibodies to Zika Virus, Campylobacter Jejuni and Gangliosides in Guillain-Barre Syndrome: A Prospective Single-Center Study From Southern India Acute Zika Inection With Concurrent Onset of Guillain-BarréSyndrome Concurrent Guillain-BarréSyndrome, Transverse Myelitis and Encephalitis Post-Zika: A Case Report and Review of the Pathogenic Role of Multiple Arboviral Immunity Neurological Complications in Patients With SARS-CoV-2 Infection: A Systematic Review Does SARS-CoV-2 Trigger Stress-Induced Autoimmunity by Molecular Mimicry? A Hypothesis Zika Virus and Autoimmunity: From Microcephaly to Guillain-BarréSyndrome, and Beyond Sars-CoV-2 and Guillain-BarréSyndrome: Molecular Mimicry With Human Heat Shock Proteins as Potential Pathogenic Mechanism Neurological Implications of COVID-19 Infections Heat-Shock Proteins in Autoimmunity Autoantibodies Against HSP70 Family Proteins Were Detected in the Cerebrospinal Fluid From Patients With Multiple Sclerosis Heat Shock Protein Immunoreactivity in CSF Correlation With Oligoclonal Banding and Demyelinating Disease Heat-Shock Proteins in Clinical Neurology Anti-Heat Shock Protein 70 Antibody Levels are Increased in Myasthenia Gravis and Guillain-BarréSyndrome Prevalence of Anti-Heat Shock Protein Antibodies in Cerebrospinal Fluids of Patients With Guillain-BarréSyndrome Guillain-BarréSyndrome Associated With Cytomegalovirus Infection Th1/Th2/Th17/Treg Cytokines in Guillain-BarréSyndrome and Experimental Autoimmune Neuritis Elevated Serum Levels of IFN-g, IL-4 and TNF-a/Unelevated Serum Levels of IL-10 in Patients With Demyelinating Diseases During the Acute Stage Il-17 and IL-22 in Cerebrospinal Fluid and Plasma are Elevated in Guillain-Barre Syndrome Intravenous Immunoglobulin Exerts Reciprocal Regulation of Th1/Th17 Cells and Regulatory T Cells in Guillain-BarréSyndrome Patients Cytokine Storm Induced by SARS-CoV-2 Infection: The Spectrum of its Neurological Manifestations Cerebrospinal Fluid in COVID-19 Neurological Complications: No Cytokine Storm or Neuroinflammation. medRxiv Guillain-BarréSyndrome: Causes, Immunopathogenic Mechanisms and Treatment The authors would like to acknowledge the support from the Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences.